7Chesnut C H, Silverman S, Andviano k, et al. A vandomized trialofna-sal spay salmon calcitonin in postmenopausalwomen with establishe osteoporosis: the prevnt recurrence of osteoporosis farcture study. PROOF study group [J] . Am J Med, 2000, 109 (6) : 267- 276.
3Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomizcd trial of nasal spray sahnon calcitonin in postmenopausal women with established ostcoporosis: the prevent recurrence of osteoporosis farcture study. PROOF Study Group. Am J Med, 2000, 109: 267-276.
4Kurnatowska I, Zygmunt A, Fijalkowska-Morawska J, el al. Hormonal activity of the hypophysial-gonadal axis versus tile mineral bone densily and speeifie markers of bone trunover ill haemodialysis population. Pol Merkur Lekarski, 2006, 20: 408-412.
5Palmer S, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev, 2005, (2): CD005015.
6Matuszkiewicz-Rowinska J, Niemczyk S, Przedlacki J, et al. Effect of salmon calcitonin on hone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism. PoX Arch Med Wewn, 2004, 112: 797-803.
7Morena M, Terrier N, Jaussent 1, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol, 2006, 17: 262-270.
8Avbersck-Luznik 1, Balon BP, Rus 1, et al. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Nephrol Dial Transplant, 2005, 20: 566-570.
9Spicehowiez U, Kokot F, Wieeek A. Markers of calciumphosphate metabolism and bones alterations in long term kidney transplant patients. Przegl Lek, 2003, 60: 690-694.
10[1]Wallach S, Rousseau G, Martin L. Effects of calcitonin on animal and in vitro models of skeletal metabolism. Bone, 1999; 25(5):509～516
